Relay Therapeutics, Inc. RLAY Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.68M-30.5% | $15.36M+83.8% | $8.36M0.0% | $8.36M+8.8% | $7.68M-23.3% | ||
| $258.14M-1.2% | $261.38M-4.6% | $274.04M-3.0% | $282.4M-9.0% | $310.5M-2.7% | ||
| $49M-13.6% | $56.71M-7.6% | $61.4M-11.0% | $69.02M-8.6% | $75.53M-1.4% | ||
| $307.14M-3.4% | $318.09M-5.2% | $335.44M-4.5% | $351.42M-6.2% | $374.65M-2.0% | ||
| -$296.46M+2.1% | -$302.74M+7.4% | -$327.09M+4.7% | -$343.06M+6.5% | -$366.97M+1.5% | ||
| -2,776.6%-805pp | -1,971.5%+1,943pp | -3,914.4%+191pp | -4,105.6%+673pp | -4,778.9%-1,057pp | ||
| $23.75M-9.5% | $26.26M-11.0% | $29.49M-6.4% | $31.52M-6.2% | $33.59M-3.4% | ||
| -$272.71M+1.4% | -$276.48M+7.1% | -$297.59M+4.5% | -$311.55M+6.6% | -$333.39M+1.3% | ||
| -2,554.1%-754pp | -1,800.5%+1,761pp | -3,561.4%+167pp | -3,728.4%+613pp | -4,341.5%-967pp | ||
| -$1.56+3.1% | -$1.61+6.4% | -$1.72+10.4% | -$1.92+12.7% | -$2.20+6.8% | ||
| -$293.61M+1.9% | -$299.18M+7.3% | -$322.79M+4.5% | -$338.15M+6.5% | -$361.7M+1.4% | ||
| -2,749.9%-802pp | -1,948.3%+1,915pp | -3,863%+184pp | -4,046.8%+663pp | -4,710.2%-1,043pp | ||
| -$296.46M+2.1% | -$302.74M+7.4% | -$327.09M+4.7% | -$343.06M+6.5% | -$366.97M+1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Relay Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.